To determine the role that DNA-PK in cancer cells played in altering their immunogenicity, we knocked out DNA-PK in B16-F10 melanoma cells (B16-F10DNA-PK–KO) (Supplemental Figure 7, A and B) and investigated mouse survival and tumor growth in response to checkpoint therapy. Here, PRKDC is linked to melanoma.